Bristol-Myers Squibb’s Hepatitis B Therapy Baraclude Will Be Available April 8

Entecavir clears FDA after a six-month priority review. Baraclude labeling includes data showing superior efficacy versus GlaxoSmithKline’s Epivir-HBV. Bristol will detail the product to the 3,500 physicians who treat most U.S. cases of hepatitis B using a Baraclude-specific sales force.